Zoznam bibliografických odkazov
BANWEL, B. 2013. Paediatric multiple sclerosis: its
uniqueness and implications for adult multiple sclerosis [online].
(presentation 24.9.2013). World congress of Neurology, European
federation of neurological societies, Vienna 2013. [cit. 2014-06-16].Available
from: : http://www.efns.org/World-Congress-of-Neurology-Vienna-2013.876.0.htm
BIELEKOVÁ, B., MARTIN R. 1999. Multiple sclerosis:
Immunotherapy. In Current treatment
options in neurology. 1999. no, 1, p.102-219.
BRONNUM-HANSEN, H., KOCH-HENRIKSEN, N., STENAGER, E.
2004. Trends in survival and cause of death in Danish patients with
multiple sclerosis. In Brain.
2004, no. 127, p 844-850.
COHEN, J.A. 2011. Fingolimod to treat multiple
sclerosis In Cohen J.A., Rudick, R.A. (ed). Multiple sclerosis therapeutics.
Cambridge University Press, 2011. p. 378-381.
COMI, G., FILIPPI, M., BARKHOF, F. et al. 2001. Effect
of early interferon treatment on conversion to definite multiple
sclerosis: a randomised study. In Lancet.
2001, no. 357, p. 1576-1582.
COMI, G., DeSTEFANO, N., FREEDMAN, M.S., et al. 2012
Comparison of two dosing frequencies of subcutaneous interferon beta1a
in patients with a first clinical event suggestive of multiple
sclerosis (REFLEX) a phase 3 randomised controlled trial. In Lancet neurology. 2012, vol. 11,
no. 1, p. 33-41.
CONFAVREUX, C., VUKUSIC, S., MOREAU, T., ADELEINE, P.
2000. Relapses and progression of disability in multiple sclerosis. In New England Journal of Medicine.
2000, no. 343, p 1430-1438.
DOUTLÍK, S.1987. Infekce a nervová soustava. Praha:
Avicenum, zdrav. nakladatelství,1987. 250 s.
GUERRE, J., FORD, C.C. 2011. Glatiramer to treat
multiple sclerosis In: Cohen, J.A., Rudick, R.A. (ed). Multiple sclerosis therapeutics.
Cambridge University Press, 2011. p. 315-325.
GOLD, S.M., VOSKUHL, R.R. 2009. Oestrogens treatment in
multiple sclerosis. In Journal of
the Neurological Sciences. 2009, vol. 286, no. 1-2, p. 99-103.
GOLDENGERG, Z. 2002. Akútne infekcie centrálneho
nervového systému. In Neurologie pro
praxi. 2002, č. 6, s. 305-307.
HAVRDOVÁ, E. 2009. Roztroušená
skleróza. 2. vyd. Praha: Maxdorf, 2009. 96 s. ISBN
978-80-73-451-87-5.
HAVRDOVÁ, E. a kol. 2013. Roztroušená skleróza. 1. vyd.
Praha: Mladá fronta, a.s., 2013. ISBN 978-80-204-3154-7.
HANDUNNETTHI, L., RAMAGOPALAN, S.V., EBERS, G. 2010.
Multiple sclerosis, vitamin D and HLA DRB 15*01. In Neurology. 2010, no. 74, p.
1905-1910.
CHATAWAY, J. SCHUERER, N., ALSANOUSI, A. et al. 2014.
Effect of high-dose simvastatin on brain atrophy and disability in
secondary progressive multiple sclerosis (MS-STAT): a randomised,
placebo-controlled, phase 2 trial. In Lancet.
2014, vol. 383, no. 9936, p. 2213-2221.
RODRIQUEZ, M., KANTARCI, O.H., PIRKO, I. 2013. Multiple
sclerosis. Oxford University Press, 2013.
KINGWELL, E., MARRIOT, J.J., JETTÉ, N. et al. 2013.
Incidence and prevalence of multiple sclerosis in Europe: a systemic
review. In BMC Neurology.
2013, no. 13, p. 128.
KRUPP, L., PATEL, L., BHISE, V. 2011. Paediatric
multiple sclerosis. In Rizvi, S.A., Coyle, P.K. (eds). Clinical
Neuroimmunology: Multiple Sclerosis and Related Disorders. Springer
Science and Business Media, 2011. ISBN 978-1-60327-859-1.
KURTZKE, J.F. 1983. Rating neurological impairment in
multiple sclerosis: an expanded disability status scale (EDSS). In
Neurology. 1983, no. 33, p. 1444-1452.
LISÁ, I., LISÝ, L. 2007. Akútne leukoencefalopatie –
diferenciálna diagnostika. In Neurológia pre. Prax. 2007, č. 2, s.
90-94.
MAKHANI, N., BANWELL, B. 2011. Environmental risk
factors for paediatric multiple sclerosis. In European Neurological Review. 2011,
vol. 6, no. 3, p. 175-180.
MARRIE, R.A., TREMLETT, H. 2011. The epidemiology of
multiple sclerosis. In Cohen, J.A., Rudick, R.A. (ed). Multiple sclerosis therapeutics.
Cambridge University Press, 2011. pp. 46-48.
O´CONNOR, P., MARRIOT, J. 2002. Differential diagnosis
and diagnostic criteria for multiple sclerosis: application and
pitfalls. [online]. p. 19-42. [cit. 2014-06-29]. Available from:
https://www.us.elsevierhealth.com/media/us/samplechapters/9781416060680/Chapter %2002.pdf
PATTEN, S.B., SVENSON, L.W., METZ, L.M. 2005. Psychotic
disorders in MS: population-based evidence of an association. In Neurology. 2005, vol. 65, no. 7, p.
1123-1125.
ROZSZPAL, H. 2001. Serózní meningitida a akutní
meningoencefalitida. Doporučené postupy MZ ČR, ČSL JEP, 2001 .
[online]. 7 s. [cit. 2014-06-22]. Dostupné na:
www.cls.cz/dokumenty2/os/r044.rtf.
SZILASIOVÁ, J. 2013. Sclerosis multiplex - klinický
obraz, diagnostika a liečba. [online]. In Edukafarm medinews. 2013, č. 2. S.
18-19. [cit. 2014-07-01]. Dostupné na: www.edukafarm.sk/data/soubory/casopisy/mediNEWS/02-2013.pdf.
SWANK, R.L., DUGAN, B.B. 1990. Effect of low saturated
fat diet in early and late cases of multiple sclerosis. In The Lancet. 1990, vol. 336, Issue
8706, p. 37-39.
TUOHY, O., COLES, A.J. 2011. Alemtuzumab to treat
multiple sclerosis In Cohen, J.A., Rudick, R.A. (ed). Multiple
sclerosis therapeutics. Cambridge University Press, 2011. pp. 395-396.
VARSÍK, P. a kol. 1999. Neurológia II. – Patogenéza a
klinika nervových chorôb. Bratislava: Lufema, spol. s.r.o., 1999.
S. 133-211. ISBN 80-967991-6-9.